Sofosbuvir & Velpatasvir



Velpatasvir 100 mg & Sofosbuvir 400 mg from Cipla :

Brand name: Hepcvel

Active Ingeridents: Sofosbuvir-400Mg-Velpatasvir-100Mg

Company Name: Cipla

Package: 28 tabs/bottle

Strength : 400 MG & 100 MG

HEPCVEL Indication :

  • Sofosbuvir 400 mg & Velpatasvir 100 mg ( Generic Epclusa ) is used alone or with ribavirin to treat chronic hepatitis C infection.
  • Sofosbuvir 400mg is in a class of antiviral medications called nucleotide HEP C Virus (HCV) NS5B polymerase inhibitors.
  • Velpatasvir100mg is in a class of antiviral medications called HCV. NS5A replication complex inhibitors.
  • Sofosbuvir 400mg and Velpatasvir 100mg works by stopping the virus that causes Hepatitis C Virus from spreading inside the Body.

HEPCVEL Dosage and Administration :

Test all patients for evidence of current or prior HBV and HCV infection by measuring hepatitis B surface antigen and hepatitis B core antibody (anti HBc) before initiating HCV treatment with HEPCVEL Tablets.

  • HEPCVEL Tablets are a two drug containing Sofosbuvir 400mg and Velpatasvir100mg in a single tablet.
  • The recommended dosage of HEPCVEL Tablets is one tablet taken orally once daily with or without food.

HEPCVEL Contraindications :

Sofosbuvir 400mg Velpatasvir 100mg ( Generic Epclusa ) FDC and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. Refer to the ribavirin prescribing information for a list of contraindications for ribavirin.

Sofosbuvir Side effects:

Common Hepcvel Tablet side effects may include:
* Headache, tired feeling;
* nausea, diarrhea; or
* sleep problems (insomnia).


Sofosbuvir 400mg and Velpatasvir 100mg ( Generic Epclusa ) is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication.


Sofosbuvir 400mg and Velpatasvir 100mg ( Generic Epclusa ) are substrates of drug transporters P-gp and BCRP while GS-331007. In vitro, slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed.